Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus

Chen Long¹, Yaling Tang¹, Jiangsheng Huang¹, Suo Liu² and Zhenhua Xing³*

¹Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Cardiothoracic Surgery, The Third Xiangya Hospital of Central South University, Changsha, China, ³Department of Emergency Medicine, The Second Xiangya Hospital, Central South University, Changsha, China

Background: Self-management of blood glucose levels to avoid hypoglycemia is vital for patients with type 2 diabetes mellitus (T2DM). The association between specific metrics of glycemic variability (glycosylated hemoglobin A1c [HbA1c] and fasting plasma glucose [FPG]) and severe hypoglycemia has not been fully studied in patients with T2DM.

Methods: In this post hoc analysis, patients with established T2DM with a high risk of cardiovascular disease were included in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. The Cox proportional hazards model was used to investigate the relationship between glycemic variability and hypoglycemia requiring medical assistance (HMA) and hypoglycemia requiring any third-party assistance (HAA). The prognostic value of HbA1c/FPG variability for our predefined outcomes was compared using Harrell’s C method.

Results: After adjusting for confounders, each increase in HbA1c variability of 1 standard deviation (SD) indicated a higher risk of HAA (hazard ratio [HR]: 1.10; 95% confidence interval [CI]: 1.03–1.16; P < 0.01) and HMA events (HR: 1.11; 95% CI: 1.03–1.20; P < 0.01). Meanwhile, each increase in FPG variability of 1 SD increased the risk of HAA (HR: 1.40; 95% CI: 1.31–1.49; P < 0.01) and HMA events (HR: 1.46; 95% CI: 1.35–1.57; P < 0.01). Meanwhile, models, including FPG variability, had better prognostic value for our predefined outcomes than HbA1c variability (P < 0.01).
Conclusions: Increased visit-to-visit variability in HbA1c and fasting glycemia is associated with a greater risk of severe hypoglycemic events in T2DM patients. FPG variability is a more sensitive indicator than HbA1c variability.

Trial registration: http://www.clinicaltrials.gov. Unique identifier: NCT00000620.

KEYWORDS
Severe hypoglycemia, HbA1c variability, fasting glycemia variability, type 2 diabetes mellitus, comparative analysis

Introduction
Type 2 diabetes mellitus (T2DM) is a major public health challenge that requires personalized lifetime management. Glucose-lowering therapy is essential to prevent T2DM progression (1, 2). The dose of glucose-lowering medications, such as insulin and metformin, are adjusted according to the monitored glucose level, which is fundamental in the management of T2DM patients. Severe hypoglycemia is defined as episodes of low plasma glucose concentration in T2DM patients receiving glucose-lowering medication, which exposes the patient to potential harm, such as confusion, disorientation, convulsion, loss of consciousness, major adverse cardiac events, and even death (3). Understanding the risk factors to immediately identify severe hypoglycemia may assist health providers, caregivers, and specialists in developing up-to-date diabetes management strategies for T2DM patients, especially those at high risk of cardiovascular disease.

The DEVOTE study demonstrated that day-to-day fasting plasma glucose (FPG) variability is associated with severe hypoglycemia (4). However, all participants in the DEVOTE study received insulin treatment only but without other oral medication, which limits its generalizability. Furthermore, there are several metrics for the assessment of glycemic variability in different settings. FPG variability is a long-term metric based on visit-to-visit FPG measurements (4, 5). Glycosylated hemoglobin A1c (HbA1c) is also a common metric to evaluate the long-term status of glycemia. The DEVOTE study only focused on the relationship between day-to-day FPG variability and the risk of severe hypoglycemia. Few studies have compared the efficacy of different metrics in predicting undesirable outcomes and explored the associations between long-term HbA1c variability and severe hypoglycemic events, ignoring the predictive role of HbA1c variability. Therefore, this post-hoc analysis aimed to determine the association between HbA1c/FPG variability and severe hypoglycemic events, as well as comparing the predictive efficacy between FPG variability and HbA1c variability.

Method
Study design
We conducted a post-hoc analysis of data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, a randomized trial involving 10,251 volunteers with T2DM from 77 clinical sites in the U.S and Canada. The detailed design and principal results have been described previously (6, 7). The ACCORD trial was a double 2×2 factorial trial that primarily investigated whether intensified control of blood glucose (HbA1c, <7.0% vs. 7.0%–7.9%), blood pressure (systolic blood pressure [SBP], <120 vs. <140 mmHg), or lipids (placebo vs. fenofibrate) could reduce the incidence of cardiovascular disease (CVD) in T2DM patients with CVD or high CVD risk. Among the enrolled patients in the ACCORD trial, 10,052 fulfilled the inclusion criteria for HbA1c variability analysis and 10,068 for FPG variability analysis. Patients with less than three measurements of HbA1c/FPG were excluded from our analysis. Included patients were then primarily randomized into two groups based on their glucose-lowering therapy: intensive group and standard group. They were then assessed every 4 months, including HbA1c/FPG measurements.

Measures of HbA1c/FPG variability
HbA1c/FPG levels were measured at a core laboratory every 4 months. HbA1c/FPG variability was defined as the intra-individual variability in HbA1c/FPG between visits using average successive variability (ASV), defined as the average absolute difference between successive values.

Abbreviations:
T2DM, Type-2 diabetes mellitus; FPG, Fasting plasma glucose; HbA1c, Glycosylated hemoglobin A1c; GV, glycemic variability; CVD, Cardiovascular disease; ACCORD, The Action to Control Cardiovascular Risk in Diabetes; SD, Standard deviation; GFR, Glomerular filtration rate; HMA, hypoglycemia requiring medical assistance; HAA, hypoglycemia requiring any third-party assistance.
Study outcomes

The occurrence of severe hypoglycemic events was the primary outcome. The researcher reiterated the course instructions every visit on how to recognize, prevent, and self-treat hypoglycemia. Severe hypoglycemia was defined as plasma glucose below 50 mg/dL (2.8 mmol/L) or presence of symptoms that promptly resolved with oral carbohydrate, intravenous glucose, or parenteral glucagon. Severe hypoglycemic events were recorded in detail at each visit. We defined two types of severe hypoglycemia events in this study, hypoglycemia requiring medical assistance (HMA) and hypoglycemia requiring any third-party assistance (HAA), as described previously. Generally, if participants had episodes requiring hospitalization or emergency medical care, they were defined as HMA. Similarly, if participants had episodes requiring assistance from any person or organization, regardless of whether they are medical or non-medical, it was defined as HAA.

Statistical analysis

The baseline characteristics of the included patients are presented as mean ± standard deviation (SD) with normal distribution or as median (25th and 75th percentiles) with skewed distribution. Continuous variables were compared using a Student’s t-test or Mann–Whitney U test according to the distribution type, and categorical variables were compared using a chi-square test. First, the participants were divided into four groups based on mean HbA1c/FPG levels. Then, for each group, they were further divided into two groups based on high variability (greater than or equal to the median) or low variability (below the median) for the comparative study to analyze the risk of HAA/HMA events. Cox proportional hazards models assessed the relationship between the ASV of HbA1c/FPG and severe hypoglycemic events. Model 1 was adjusted for mean FPG and HbA1c levels, age, sex, race, and glucose control strategy (intensive/standard). Model 2 was adjusted for model 1 in addition to a history of CVD, education, depression (yes/no), cigarette smoking (current or not), diabetes duration, alcohol consumption (mean days per week), body mass index, low-density lipoprotein, high-density lipoprotein, and glomerular filtration rate. Restricted cubic splines with four knots in the 5th, 35th, 65th, and 95th percentiles were used to explore the nonlinear association between the ASV of HbA1c/FPG and our predefined severe hypoglycemia events. We found no evidence of violation of the proportional hazard assumption based on tests using Schoenfeld residuals. Discrimination in the models was assessed using Harrell’s C-statistic. The prognostic value of ASV of HbA1c/FPG for our predefined outcomes was compared. Sensitivity analysis was performed to verify the robustness of our results. First, to avoid bias in the Cox proportional hazards models, we used competing risk models (modeling sub-distributional hazard ratios) for our predefined outcomes in the sensitivity analysis. Then, we applied competing event of all-cause mortality as a permanent condition to prevent the occurrence of our predefined outcomes. Next, we conducted interaction and stratified analyses considering age (<75 and ≥75 years), sex, race, duration of diabetes (≥10 or <10 years), and glucose control strategy (intensive or standard). All statistical analyses were two-sided, and a P-value of <0.05 was considered statistically significant. All analyses were performed using STATA17.0 software purchased from StataCorp LLC (College Station, TX, USA).

Result

Patient characteristics

The baseline characteristics of the included participants are presented in Table 1 based on HbA1c/FPG variability (below the median versus greater than or equal to the median). The median number of HbA1c measurements was 14 (interquartile range [IQR]: 11–17) and FPG measurement was 11 (IQR: 8–16) (Supplementary Figures S1, S2). The median HbA1c and FPG variability were 0.55 ± 0.29 and 30.9 ± 17.5, respectively (Supplementary Figures S3, S4). The mean HbA1c and FPG during the follow-up period were 7.4% ± 0.86% and 144.6 ± 33.9 mg/dL, respectively. Patients with standard glucose control had a higher HbA1c/FPG variability. Additionally, the high variability group had higher rates of occurrence of HAA/HMA events in the Q1 to Q4 quartiles of mean HbA1c/FPG levels (Figure 1).

HbA1c/FPG variability and hypoglycemia

For the analysis of HbA1c variability, the patients were grouped into four quartiles based on HbA1c/FPG variability. Considering the lowest HbA1c variability quartile (Q1) as a reference, Q2 had an increase in the risk of HAA events by 19%, Q3 by 37%, and Q4 by 42%. Furthermore, Q2 had an increase in the risk of HMA events of 21%, Q3 by 33%, and Q4 by 57% in the fully adjusted model 2 (Table 2). Similarly, for FPG variability, Q2 had an increase in the risk of HAA events of 17%, Q3 by 48%, and Q4 by 120%, whereas Q2 had an increase in the risk of HMA events of 18%, Q3 by 65%, and Q4 by 141% in the fully adjusted model 2 (Table 2).

When HbA1c/FPG variability was used as a continuous variable in model 2, each increase in HbA1c variability of 1 SD increased the risk of HAA [hazard ratio (HR): 1.10; 95% confidence interval (CI), 1.03–1.16; P < 0.01] and HMA events (HR: 1.11; 95% CI: 1.03–1.20; P < 0.01; model 2). Meanwhile, each increase in FPG variability of 1 SD increased the risk of
HAA (HR: 1.40; 95% CI: 1.31–1.49; P < 0.01; model 2) and HMA events (HR: 1.46; 95% CI: 1.35–1.57; P < 0.01).

In Figure 2, we used restricted cubic splines to flexibly model and visualize the relationship between FPG/HbA1c variability and our predefined endpoints. This illustrated that the risk of HAA/HMA events increased sharply with the increase in FPG variability without any plateau period (Figures 2A, B). However, the risk of HAA/HMA did not increase and reached a plateau period, when HbA1c variability exceeded 0.7 (Figures 2C, D).

Sensitivity and subgroup analysis

We used the competing risk model instead of the Cox proportional risk model in sensitivity analysis, which yielded consistent results (Supplementary Table 1). Furthermore, subgroup analysis results are summarized in Figure 3. The results showed that no factor played an interactive role in the association between HbA1c variability and HAA/HMA events, except glucose control therapy, suggesting a stronger effect of HbA1c variability on the risk of HAA/HMA events in patients with intensive glucose control. Similar effects were noted in the association between FPG variability and HAA/HMA events.

Comparative analysis of predictive efficacy between HbA1c and FPG variabilities

In the comparative analysis, Harrell’s C method was applied to evaluate the predictive efficacy of HbA1c and FPG variabilities in HAA/HMA events. Table 3 shows that FPG variability was...
more powerful in predicting HAA/HMA events than HbA1c variability in both adjusted models 1 and 2.

Discussion

In this post-hoc analysis of participants with established T2DM with a high risk of CVD in the ACCORD trial, the two long-term metrics of glycemic variability (HbA1c and FPG) were strongly associated with an increased risk of severe hypoglycemia events, and the associations were independent of mean HbA1c/FPG. Moreover, by comparing the efficacy of these two metrics, we concluded that FPG variability was better than HbA1c variability in predicting both HMA and HAA events. In sensitivity analyses, we found that the glucose control strategy moderated the association between HbA1c/FPG variability and our predefined outcomes, suggesting that patients who received an intensive glucose strategy were more likely to develop hypoglycemia even if they had the same HbA1c/FPG variability.

Both HbA1c variability and FPG variability can be categorized into long-term metrics of glycemic variability because they were obtained through visit-to-visit determinations over a certain period of time (8). Despite there being no comprehensive consensus on clinical significance of glycemic variability, studies showed that FPG variability is associated with increased risk of adverse events and specific diseases, including cardiovascular events, peripheral neuropathy, retinopathy, and arterial stiffness (9–13). Clinical practice and research have focused on HbA1c in T2DM patients, rather than the potential role of HbA1c variability (14–16). Our results suggest that higher HbA1c variability increases the incidence of severe hypoglycemia, indicating that it is important to carefully observe in T2DM patients with higher HbA1c variability and take precautions, even when acceptable levels of HbA1c and FPG are achieved. In the SWITCH Trials, DeVries JH et al. concluded that higher day-to-day fasting blood glucose variability is associated with an increased risk of overall symptomatic severe hypoglycemia in insulin-treated patients (5). Our analysis of data from the ACCORD trial also demonstrated that higher long-term visit-to-visit glycemic variability (FPG/HbA1c variability) increased the risk of severe hypoglycemia. Additionally, studies have shown that the choice of glucose control therapy is a potentially modifiable risk factor for hypoglycemia (17–19). Furthermore, previous studies have demonstrated that fasting blood glucose variability is influenced by glucose-lowering medications (5, 20). Our study supported

FIGURE 1
Quartiles of HbA1c/FPG variability and rate HAA/HMA Events a Function of Baseline HbA1c/FPG. (A, B) FPG (Fasting Plasma Glucose) and FPG variability. Q1 is defined as a FPG mean located in first quartile, Q2 located a FPG mean in second quartile, Q3 a FPG mean located in third quartile and Q4 a FPG mean located in a fourth quartile; (C, D) HbA1c (hemoglobin A1c) and HbA1c variability. Q1 is defined as a HbA1c mean located in first quartile, Q2 a HbA1c mean located in second quartile, Q3 a HbA1c mean located in third quartile and Q4 a HbA1c mean located in fourth quartile.
TABLE 2  Association between HbA1c/FPG variability and predefined outcomes.

| Incidence rate per 1000 person years | HR (95%CI) |
|--------------------------------------|------------|
|                                      | Model 1    | Model 2    |
|                                       | HbA1c variability                             |
| HAA                                  |           |           |
| Q1                                   | 21.4      | Ref       |
| Q2                                   | 26.4      | 1.22(1.03-1.45) | 1.19(1.00-1.42) |
| Q3                                   | 29.7      | 1.45(1.17-1.64) | 1.37(1.16-1.63) |
| Q4                                   | 32.9      | 1.36(1.13-1.63) | 1.42(1.18-1.71) |
| P for trend                          | <0.01*    | <0.01*    |
| Per SD increase                      | 1.06(1.00-1.13) | 1.09(1.03-1.16) |
|                                       | FPG variability                              |
| HAA                                  |           |           |
| Q1                                   | 17.1      | Ref       |
| Q2                                   | 22.1      | 1.24(1.02-1.50) | 1.17(0.97-1.42) |
| Q3                                   | 29.2      | 1.64(1.36-1.97) | 1.48(1.23-1.78) |
| Q4                                   | 42.4      | 2.51(2.08-3.04) | 2.20(1.81-2.67) |
| P for trend                          | <0.01*    | <0.01*    |
| Per SD increase                      | 1.07(1.00-1.15) | 1.10(1.02-1.19) |
|                                       | HMA variability                               |
| Q1                                   | 10.3      | Ref       |
| Q2                                   | 13.2      | 1.22(0.96-1.55) | 1.18(0.92-1.50) |
| Q3                                   | 19.6      | 1.81(1.44-2.27) | 1.65(1.31-2.08) |
| Q4                                   | 28.9      | 2.73(2.16-3.47) | 2.41(1.89-3.07) |
| P for trend                          | <0.01*    | <0.01*    |
| Per SD increase                      | 1.55(1.44-1.67) | 1.47(1.37-1.59) |

*P value<0.05

Model 1: FPG, HbA1c, age, sex, race, glycemic control strategy.
Model 2: FPG, HbA1c, age, sex, race, glucose control strategy, history of cardiovascular disease, education, depression, cigarette, duration of diabetes, alcohol, body mass index, low-density lipoprotein, high-density lipoprotein, glomerular filtration rate.

This perspective and found that glucose control therapy played an interactive role in the association between HbA1c/FPG variability and HAA/HMA events in the subgroup analysis (21, 22). Patients receiving standard glucose therapy had higher glycemic variability than those receiving intensive glucose therapy.

Different types of antidiabetic treatments affect glycemic variability and hypoglycemia to various extents in the T2DM population. The ultimate goal for them is to obtain a long-term stable plasma glucose level that has been repeatedly highlighted in various clinical guidelines.

The strengths of this study are that it exploited the data from a large cohort of patients with established T2DM and determined severe hypoglycemic episodes in different glucose-lowering strategies. While a previous study focused on the relationship between a specific single metric of glycemic variability and single severe hypoglycemia event, our study applied multiple metrics (HbA1c/FPG variability) and two types of severe hypoglycemia events (HMA/HAA). To the best of our knowledge, our study is the first to compare the predictive efficacy of HbA1c and FPG using HMA and HAA events.

Severe hypoglycemia is a common complication of T2DM, which is harmful to patient health, with an annual incidence of 0.75–33.8 per 1,000 patients (23–25). Meanwhile, severe hypoglycemia is an distressing experience for these patients with glycemic control therapy that increases the risk of developing physical injuries and emotional burden, affecting quality of life because episodes of severe hypoglycemia could result in cognitive disorientation and loss of consciousness, leading to subsequent accidents and injury, especially in the elderly population (26, 27). The American Diabetes Association working group emphasized that people with diabetes would develop potential harm from all episodes of hypoglycemic events (28). Deleterious effects of hypoglycemia on the cardiovascular system were reported, and multiple mechanisms, including disrupting normal function of blood coagulation and endothelial cells, activating inflammation pathways, and inducing sympahto-adrenal response (3).

Researchers strive to identify risk factors to predict the occurrence of severe hypoglycemia. Risk factors associated with severe hypoglycemia include age, insulin and sulfonylurea use, and cognitive impairment (29, 30). Increased glycemic variability is a risk factor for severe hypoglycemia. Patients with greater glycemic variability tend to be older, with a long history of diabetes, and less medical compliance, which in turn, leads to a higher incidence of hypoglycemia. (4,5) While there are different metrics representing glycemic variability in various aspects, the association between glycemic variability and severe hypoglycemia remains unclear because of the specific metrics applied in studies and heterogeneity of study design. Moreover, preventing hypoglycemia is prioritized by healthcare providers because it reduces the incidence of cardiac diseases, including cardiac arrhythmia and CVD (31, 32). Future research could shift from emphasizing single metrics to combined glycemic-related metrics to improve the efficacy of predicting hypoglycemic events and reduce their occurrence. The treatment could be various “cocktails” for T2DM patients rather than rigid one, or two cuts-off of metrics based on glycemic-related metrics since changing the glucose therapy would not always adjust all metrics of T2DM patients to an ideal level in a clinical setting.
Association of predicted HAA/HMA event and HbA1c/FPG variability (A) Association of FPG variability and HAA event; (B) Association of FPG variability and HMA event; (C) Association of HbA1c variability and HAA events; (D) Association of HbA1c variability and HMA event. Hazard ratios are indicated by solid lines and 95% CIs by areas between two dotted lines. (Reference point is the lowest value for each curve) The Reference knots were placed at the 5th, 35th, 65th, 95th, centiles of HbA1c/FPG variability distribution. HbA1c/FPG variability were adjusted using model 2.

Hazard ratios per one standard deviation increase in the HbA1c/FPG variability for the predefined endpoints. Each stratification was adjusted for all factors in model 2 (fasting plasma glucose, plasma glucose control strategy, age, race, female, history of cardiovascular disease, education, depression, cigarette, duration of diabetes, alcohol, body mass index, low-density lipoprotein, high-density lipoprotein, glomerular filtration rate, HbA1c), except for the stratification factor itself. HAA, hypoglycemia requiring any third-party assistance; HMA, hypoglycemia requiring medical assistance; HbA1c, Hemoglobin A1c; FPG, Fasting plasma glucose.
Our study has some limitations. First, the included patients with CVD or a high risk of CVD had a long duration of T2DM, which put them at a higher risk of hypoglycemia and other adverse events. This may have affected the generalizability of this study, especially in young patients with T2DM with lower CVD risk. Second, the patient characteristics were only measured during inception, without re-evaluation on the follow-up period. Third, all included patients were from the US and Canada and these results may not be applicable to other ethnicities. Another limit to the study is the lack of data on dietary habit and lifestyle modifications, as not all food has the same glycemic index and may be a limitation for FPG/HbA1c evaluation (33).

Conclusions

T2DM patients with increasing HbA1c and FPG variabilities are at a greater risk of severe hypoglycemia. Additionally, FPG variability is a more sensitive indicator than HbA1c variability. Therefore, clinicians should consider the variability of both HbA1c and FPG as indicators for predicting severe hypoglycemia events and consider them as potential targets for treating patients with T2DM.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://biolincc.nhlbi.nih.gov/home/.

Ethics statement

The studies involving human participants were reviewed and approved by http://www.clinicaltrials.gov. Unique identifier: NCT00000620). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

ZX designed the study and provided methodological expertise. CL and SL drafted the manuscript. CL, SL, YT, JH, and ZX drafted the tables and figures and performed statistical analysis. All authors contributed to the article and approved the submitted version.

Funding

This work was supported in part by the National Science Foundation of China project 82000298 to ZX.

Acknowledgments

All authors read, provided critical feedback, and approved the final manuscript. ZX is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.975468/full#supplementary-material

References

1. A. American Diabetes. Standards of medical care in diabetes-2022 abridged for primary care providers. Clin Diabetes (2022) 40:10–38. doi: 10.2337/cd22-s003
2. C. American Diabetes Association Professional Practice, Drasnin B, Arora VR, Bakris G, Benson G, Brown FM, et al. 16. diabetes care in the hospital: Standards of medical care in diabetes-2022. Diabetes Care (2022) 45:S244–53. doi: 10.2337/dc22-S016
3. I.H.S. Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol (2019) 7:385–96. doi: 10.1016/S2213-8587(18)30315-3
4. Zimman B, Marso SP, Poulier NR, Emerson SS, Pieber TR, Pratley RE, et al. Day-to-day fasting glycemic variability in DEVOTE associations with severe hyperglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia (2018) 61:48–57. doi: 10.1007/s00125-017-4423-z
5. DeVries JB, Bailey TS, Bhagava A, Gerty G, Gumprecht J, Heller S, et al. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH trials. Diabetes Obes Metab (2019) 21:622–30. doi: 10.1111/dobm.13565
6. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 99:231–34. doi: 10.1016/j.amjcard.2007.03.003
7. Gerstein HC, Riddle MC, Kendall DM, Cohen RM, Goland R, Feinglos MN, et al. Glycemia treatment strategies in the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol (2007) 99:341–46. doi: 10.1016/j.amjcard.2007.03.004
8. DeVries JB. Glucose variability: where it is important and how to measure it. Diabetes (2013) 62:1405–8. doi: 10.2337/db12-1610
9. Barzegar N, Ramezanianhi A, Tohidi M, Arzai F, Hadaegh F. Long-term glucose variability and incident cardiovascular diseases and all-cause mortality events in subjects with and without diabetes: Tehran lipid and glucose study. Diabetes Res Clin Pract (2018) 178:108492. doi: 10.1016/j.diabres.2018.108492
10. Pui YW, Lin CH, Lee JT, Chang MH. Variation of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes. Diabetes Metab (2018) 44:129–34. doi: 10.1016/j.diabetem.2018.01.004
11. Takao T, Inoue K, Saka M, Yanagisawa H, Iwamoto Y. Optimal cutoff values of fasting plasma glucose (FPG) variability for detecting retinopathy and the threshold of FPG levels for predicting the risk of retinopathy in type 2 diabetes: A longitudinal study over 27 years. Diabetes Res Clin Pract (2018) 140:228–35. doi: 10.1016/j.diabres.2018.03.051
12. Wang A, Liu X, Xu J, Han X, Su Z, Chen S, et al. Visit-to-Visit variability of fasting plasma glucose and the risk of cardiovascular disease and all-cause mortality in the general population. J Am Heart Assoc (2017) 6(12):e006757. doi: 10.1161/JAHA.117.006757
13. Zhang Y, Wu S, Li M, Wang T, Xu M, Lu J, et al. Long-term glycemic variability is associated with arterial stiffness in Chinese adults. Front Endocrinol (Lausanne) (2021) 12:711540. doi: 10.3389/fendo.2021.711540
14. Kim KJ, Choi J, Bae JH, Kim KJ, Yoo HJ, Seo JA, et al. Time to reach target glycosylated hemoglobin is associated with long-term durable glycemic control and risk of diabetic complications in patients with newly diagnosed type 2 diabetes mellitus: A 6-year observational study. Diabetes Metab J (2021) 45:368–78. doi: 10.4093/dmj.2020.0046
15. Lee J, Cho JH. Early glycosylated hemoglobin target achievement predicts clinical outcomes in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Metab J (2021) 45:357–8. doi: 10.4093/dmj.2021.0078
16. Wan KS, Moy FM, Mustapha FI, Ismail M, Harri NN. Changes in body mass index, glycosylated hemoglobin, A1C, blood pressure, and LDL-cholesterol among type 2 diabetes patients in Malaysia: A population-based longitudinal study. J Diabetes (2013) 13:915–29. doi: 10.1111/1753-0432.12036
17. Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care (2017) 40:468–75. doi: 10.2337/dc16–0985
18. Quilliam BL, Simeone JC, Ozbay AB. Risk factors for hypoglycaemia-related hospitalization in patients with type 2 diabetes: a nested case-control study. Clin Ther (2011) 33:1781–91. doi: 10.1016/j.clinthera.2011.09.020
19. O.T. Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care (2015) 38:22–8. doi: 10.2337/dc14-1329
20. Yamamoto C, Miyoshi H, Fujwara Y, Kameda R, Ichiyama M, Nomoto H, et al. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus. Endocr J (2016) 63:53–60. doi: 10.1507/endocrj.EJ15-0438
21. Catariano A, Galiero R, Pafundi PC. Metformin for type 2 diabetes. JAMA (2019) 322:1312. doi: 10.1001/jama.2019.11489
22. Salvatore T, Galiero R, Catariano A, Vetrano E, Rinaldi L, Covelli F, et al. Effects of metformin in heart failure: From pathophysiological rationale to clinical evidence. Biomolecules (2021) 11(12):1834. doi: 10.3390/biom11121834
23. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycemia complicating type 2 diabetes: the freemantle diabetes study. J Clin Endocrinol Metab (2010) 95:2240–7. doi: 10.1210/jc.2009-2828
24. Ikeda Y, Kubo T, Oda E, Abe M, Tokita S. Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective diagnosis procedure combination database analysis. J Diabetes Investig (2018) 9:923–36. doi: 10.1111/jdi.12778
25. Katakura M, Naka M, Kondo T, Nishii N, Komatsu M, Sato Y, et al. Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects: Nagano study. Diabetes Care (2003) 26:638–44. doi: 10.2337/diabetes.53.3.638
26. Freeman J. Management of hypoglycemia in older adults with type 2 diabetes. Postgrad Med (2019) 13:241–50. doi: 10.1080/00325481.2019.1578590
27. Punthakee Z, Miller ME, Launor LJ, Williamson JD, Lazar RM, Cukierman-Yaffe T, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care (2012) 35:797–83. doi: 10.2337/dc11–1855
28. Sequist ER, Anderson J, Childs B, Czerwinski P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society. J Clin Endocrinol Metab (2013) 98:1845–59. doi: 10.1210/jc.2012–4127
29. Lee SE, Kim KA, Son KJ, Song SO, Park KH, Park SH, et al. Trends and risk factors in severe hypoglycemia among individuals with type 2 diabetes in Korea. Diabetes Res Clin Pract (2017) 178:10846. doi: 10.1016/j.diabres.2017.108496
30. Silbert R, Salcido-Montenegro A, Rodriguez-Gutierrez R, Katabi A, McCoy RG. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. *Curr Diabetes Rep* (2018) 18:53. doi: 10.1007/s11892-018-1018-0

31. Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. *Curr Med Res Opin* (2017) 33:797–801. doi: 10.1080/03007995.2016.1277199

32. Andersen A, Bagger JL, Sorensen SK, Buldassarre MPA, Pedersen-Bjergaard U, Forman JL, et al. Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study. *Cardiovasc Diabetol* (2021) 20:241. doi: 10.1186/s12933-021-01425-0

33. Esposito K, Ciotola M, Sasso FC, Cozziolino D, Saccomanno F, Assaloni R, et al. Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. *Nutr Metab Cardiovasc Dis* (2007) 17:274–9. doi: 10.1016/j.numecd.2005.11.014